Cipher Pharmaceuticals Inc
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of… Read more
Cipher Pharmaceuticals Inc (CPHRF) - Total Assets
Latest total assets as of September 2025: $147.50 Million USD
Based on the latest financial reports, Cipher Pharmaceuticals Inc (CPHRF) holds total assets worth $147.50 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Cipher Pharmaceuticals Inc - Total Assets Trend (2004–2024)
This chart illustrates how Cipher Pharmaceuticals Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Cipher Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Cipher Pharmaceuticals Inc's total assets of $147.50 Million consist of 23.7% current assets and 76.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 11.0% |
| Accounts Receivable | $13.86 Million | 8.5% |
| Inventory | $5.79 Million | 3.6% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $78.75 Million | 48.5% |
| Goodwill | $17.45 Million | 10.7% |
Asset Composition Trend (2004–2024)
This chart illustrates how Cipher Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cipher Pharmaceuticals Inc's current assets represent 23.7% of total assets in 2024, a decrease from 76.3% in 2004.
- Cash Position: Cash and equivalents constituted 11.0% of total assets in 2024, down from 46.5% in 2004.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 58.0% of total assets, an increase from 0.0% in 2004.
- Asset Diversification: The largest asset category is intangible assets at 48.5% of total assets.
Cipher Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Cipher Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Cipher Pharmaceuticals Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Cipher Pharmaceuticals Inc generates 0.21x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, Cipher Pharmaceuticals Inc generates $7.10 in net profit.
Cipher Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.30 | 2.00 | 2.03 |
| Quick Ratio | 0.98 | 1.64 | 1.94 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $6.23 Million | $ 14.55 Million | $ 10.21 Million |
Cipher Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Cipher Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.38 |
| Latest Market Cap to Assets Ratio | 0.82 |
| Asset Growth Rate (YoY) | 88.9% |
| Total Assets | $162.51 Million |
| Market Capitalization | $133.52 Million USD |
Valuation Analysis
Near Book Valuation: The market values Cipher Pharmaceuticals Inc's assets close to their book value ( 0.82x), suggesting investors view the company's assets at approximately fair value.
Rapid Asset Growth: Cipher Pharmaceuticals Inc's assets grew by 88.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Cipher Pharmaceuticals Inc (2004–2024)
The table below shows the annual total assets of Cipher Pharmaceuticals Inc from 2004 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $162.51 Million | +88.90% |
| 2023-12-31 | $86.03 Million | +16.61% |
| 2022-12-31 | $73.78 Million | +42.84% |
| 2021-12-31 | $51.65 Million | +16.66% |
| 2020-12-31 | $44.28 Million | -4.69% |
| 2019-12-31 | $46.45 Million | -16.58% |
| 2018-12-31 | $55.69 Million | -11.79% |
| 2017-12-31 | $63.13 Million | -18.44% |
| 2016-12-31 | $77.41 Million | -29.40% |
| 2015-12-31 | $109.65 Million | +884.67% |
| 2014-12-31 | $11.14 Million | -78.66% |
| 2013-12-31 | $52.17 Million | +136.40% |
| 2012-12-31 | $22.07 Million | +53.71% |
| 2011-12-31 | $14.36 Million | -11.21% |
| 2010-12-31 | $16.17 Million | +14.23% |
| 2009-12-31 | $14.16 Million | +5.20% |
| 2008-12-31 | $13.46 Million | -28.80% |
| 2007-12-31 | $18.90 Million | -2.11% |
| 2006-12-31 | $19.31 Million | -12.78% |
| 2005-12-31 | $22.14 Million | -31.59% |
| 2004-12-31 | $32.36 Million | -- |